Clinical Trial Update: DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial update for DAPERB 3,4-DiAminoPyridine in Brugada Syndrome; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brugada Syndrome

Drugs mentioned

• DAPERB 3,4-DiAminoPyridine (null)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Brugada Syndrome | Phase 3 | Status: TERMINATED